Daxas for COPD Therapy (DACOTA).
Phase of Trial: Phase IV
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms DACOTA
- Sponsors Takeda; Takeda Pharmaceuticals International GmbH
- 04 May 2012 Takeda Global Research and Development Center added as company and lead trial centre as reported by ClinicalTrials.gov.
- 04 May 2012 Planned end date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.